Cencora, Inc. $COR Shares Purchased by Fort Washington Investment Advisors Inc. OH

Key Points

• Fort Washington Investment Advisors increased its Cencora stake by 81.5% in the third quarter, buying 201,057 additional shares and bringing its holdings to 447,763 shares valued at approximately $139.9 million.
• Cencora reported quarterly EPS of $4.48, exceeding estimates of $4.35, while revenue rose 5.1% year over year to $84.75 billion. The company also maintains a $0.60 quarterly dividend, equivalent to a 0.7% yield.
• Analysts hold a “Moderate Buy” consensus rating, with an average price target of $365.69; shares recently opened at $335.85, up 1.7%, while institutional investors own 97.52% of the stock.

Fort Washington Investment Advisors Inc. OH increased its position in shares of Cencora, Inc. (NYSE:COR - Free Report) by 81.5% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 447,763 shares of the company's stock after purchasing an additional 201,057 shares during the quarter. Fort Washington Investment Advisors Inc. OH owned approximately 0.23% of Cencora worth $139,917,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently added to or reduced their stakes in COR. Steph & Co. lifted its holdings in Cencora by 23.5% in the 1st quarter. Steph & Co. now owns 168 shares of the company's stock valued at $53,000 after purchasing an additional 32 shares in the last quarter. Cornerstone Wealth Group LLC boosted its stake in Cencora by 1.6% during the 1st quarter. Cornerstone Wealth Group LLC now owns 2,434 shares of the company's stock worth $760,000 after purchasing an additional 38 shares during the last quarter. OLD National Bancorp IN grew its holdings in shares of Cencora by 0.4% during the first quarter. OLD National Bancorp IN now owns 9,964 shares of the company's stock worth $3,130,000 after buying an additional 40 shares in the last quarter. Staley Capital Advisers Inc. grew its holdings in shares of Cencora by 0.7% during the first quarter. Staley Capital Advisers Inc. now owns 6,127 shares of the company's stock worth $1,925,000 after buying an additional 40 shares in the last quarter. Finally, Elmwood Wealth Management Inc. grew its holdings in shares of Cencora by 0.9% during the second quarter. Elmwood Wealth Management Inc. now owns 4,314 shares of the company's stock worth $1,221,000 after buying an additional 40 shares in the last quarter. 97.52% of the stock is owned by institutional investors and hedge funds.

Cencora Stock Up 1.7%

Shares of NYSE COR opened at $335.85 on Thursday. The company has a quick ratio of 0.58, a current ratio of 0.93 and a debt-to-equity ratio of 3.53. The business's 50 day moving average is $319.66 and its two-hundred day moving average is $302.88. Cencora, Inc. has a 52-week low of $244.82 and a 52-week high of $377.54. The firm has a market cap of $64.09 billion, a price-to-earnings ratio of 24.95, a PEG ratio of 1.69 and a beta of 0.58.

Cencora (NYSE:COR - Get Free Report) last released its quarterly earnings results on Wednesday, August 5th. The company reported $4.48 EPS for the quarter, topping the consensus estimate of $4.35 by $0.13. The business had revenue of $84.75 billion during the quarter, compared to analyst estimates of $84.31 billion. Cencora had a return on equity of 125.45% and a net margin of 0.79%. The company's quarterly revenue was up 5.1% on a year-over-year basis. During the same period last year, the business posted $4.00 earnings per share. Research analysts predict that Cencora, Inc. will post 17.87 EPS for the current year.

Cencora Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, August 31st. Shareholders of record on Friday, August 14th were given a $0.60 dividend. This represents a $2.40 annualized dividend and a yield of 0.7%. The ex-dividend date of this dividend was Friday, August 14th. Cencora's payout ratio is currently 17.83%.

Wall Street Analyst Weigh In

COR has been the subject of a number of recent research reports. Weiss Ratings upgraded shares of Cencora from a "buy (b-)" rating to a "buy (b)" rating in a research report on Tuesday, October 6th. Morgan Stanley boosted their price target on shares of Cencora from $342.00 to $346.00 and gave the stock an "overweight" rating in a research report on Friday, August 7th. Bank of America boosted their price target on shares of Cencora from $285.00 to $310.00 in a research report on Tuesday, July 21st. Royal Bank Of Canada reaffirmed a "sector perform" rating and set a $330.00 price objective on shares of Cencora in a research note on Tuesday, September 8th. Finally, Wall Street Zen raised shares of Cencora from a "hold" rating to a "buy" rating in a research note on Saturday, August 8th. Fourteen research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $365.69.

Insiders Place Their Bets

In other Cencora news, EVP Elizabeth Campbell sold 11,300 shares of the business's stock in a transaction dated Monday, August 24th. The shares were sold at an average price of $324.12, for a total transaction of $3,662,556.00. Following the sale, the executive vice president directly owned 19,455 shares in the company, valued at $6,305,754.60. This represents a 36.74% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.38% of the stock is currently owned by corporate insiders.

Cencora Profile

Cencora, formerly known as AmerisourceBergen, is a global pharmaceutical solutions company that sources, distributes and supports the delivery of medicines and healthcare products. The company serves pharmaceutical manufacturers, healthcare providers, pharmacies and animal-health customers through its supply-chain and commercialization services.

Its activities include pharmaceutical and specialty-product distribution, manufacturer services, specialty logistics, clinical-trial support, patient-support programs and other services designed to help bring medicines to market and improve access to treatment.

Want to see what other hedge funds are holding COR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cencora, Inc. (NYSE:COR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.